Topical ruxolitinib for treatment of mycosis fungoides and lymphomatoid papulosis
Activation of the JAK/STAT signalling pathway plays a pivotal role in the pathogenesis of cutaneous T-cell lymphomas. Therefore, inhibition of this cardinal pathway is a promising novel treatment option. Here, we report the first evidence of rapid response of lymphomatoid papulosis and mycosis fungoides upon topical application of the Janus kinase inhibitor ruxolitinib.
Authors
- Katja Maurus (ORCID: https://orcid.org/0000-0002-3093-3114)
- Andreas Rosenwald (ORCID: https://orcid.org/0000-0001-7282-8374)
- Marion Wobser (ORCID: https://orcid.org/0000-0002-6293-2554)
- Matthias Goebeler (ORCID: https://orcid.org/0000-0001-7095-9848)
Institutions
- University of Würzburg (DE)
- Comprehensive Cancer Center Mainfranken (DE)
- Universitätsklinikum Würzburg (DE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1093/bjd/ljaf180
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00